Skip to main content

Day: August 6, 2025

West Red Lake Gold Provides Madsen Mine Operations Update

VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) — West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF) is pleased to provide an update on ramp-up activities at the Madsen Mine in Red Lake, Ontario. “July was a good month for Madsen and our mine operations team, and we continue to track to plan on our ramp up,” said Shane Williams, President and CEO. “Mine ramp-up is about adding equipment, developing access to high-priority mining areas, and increasing operational efficiency until the mine consistently produces the targeted daily tonnage at the targeted grade. During July, all these ramp-up elements played a positive role at Madsen. The mill achieved an average of 94% recovery over the month while processing 500-800 tonnes per day. Additionally, material mined from...

Continue reading

Facephi Launches “Advanced Injection Defense” Against Deepfakes and AI-Powered Injection Attacks

Facephi Launches “Advanced Injection Defense” Against Deepfakes and AI-Powered Injection AttacksNew AI-powered add-on for Facephi’s Behavioral Biometrics Solution to detect and block injection attacks in real time Protects against deepfakes, device emulation, and manipulated capture channels with forensic-level analysis Easily integrates into onboarding and authentication workflows across banking, healthcare, telecom, and public sectorsAlicante, August 06, 2025 – Facephi Biometría, SA (BME Growth: FACE; Euronext Growth Paris: ALPHI) (“Facephi” or the “Company”), a Spanish tech leader in global digital identity protection and verification, has launched Advanced Injection Defense — a powerful new add-on to its Behavioral Biometrics Solution that brings enhanced protection against deepfakes, spoofing, and manipulated...

Continue reading

Eurocastle Releases First Half 2025 Financial Results, 2025 AGM Results and PDMR Dealing Notification

EUROCASTLE INVESTMENT LIMITED                                        FOR IMMEDIATE RELEASEContact:        Oak Fund Services (Guernsey) LimitedCompany AdministratorAttn: Nicole BarnesTel: +44 1481 723450         Eurocastle Releases First Half 2025 Financial Results, 2025 AGM Results and PDMR Dealing Notification Guernsey, 6 August 2025 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today has released its financial report for the six months ended 30 June 2025. In addition, the Company announces the results of its 2025 Annual General Meeting held yesterday, 5 August 2025, at which all ordinary and extraordinary resolutions tabled were approved.ADJUSTED NET ASSET VALUE (“NAV”)1 of €15.2 million, or €15.19 per share2 (€11.1 million, or €11.43 per share as at Q1 2025).Increase of €3.76 per share...

Continue reading

Novo Nordisk’s sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025

Bagsværd, Denmark, 6 August 2025 – Financial report for the period 1 January 2025 to 30 June 2025                                                                                                                                                            Operating profit increased by 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Sales in US Operations increased by 16% in Danish kroner (17% at CER). Sales in the US were positively impacted by gross-to-net sales adjustments related to prior years, including an adjustment related to the 340B provision of around DKK 3 billion in the second quarter of 2025. Sales in International Operations increased by 16% in Danish kroner (19% at CER). Sales within Diabetes and Obesity care increased by 16% in Danish kroner to DKK 145.4 billion (18% at CER), mainly...

Continue reading

Report for the six-month period ended 30 June 2025

HighlightsProportionate power generation amounted to 439 GWh for the reporting period, and in addition, the Company had 20 GWh of compensated volumes relating to ancillary services and availability warranties, bringing the total proportionate power generation, including these compensated volumes, to 459 GWh. In July 2025, the Company completed the sale of a 76 MW solar project in Germany for a total consideration of MEUR 4.0, with MEUR 2.0 paid at closing and the remaining consideration contingent upon municipal and legislative approvals. Reached the ready-to-permit milestone for a second solar project in Germany of 93 MW, and advanced seven large-scale solar and battery projects in the UK towards final grid confirmation under the ongoing grid reform. Entered into financial hedges covering approximately 40 percent of the second-half...

Continue reading

ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors

Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific.Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds.EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces the appointment of Lucas Buchanan as a non-executive member of its Board of Directors. “We are delighted to welcome Lucas Buchanan to our Board of Directors,”...

Continue reading

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).  The RMAT designation was established under the U.S. 21st Century Cures Act to accelerate development and review of promising cell and gene therapies for serious or life-threatening conditions. To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has the potential to treat, modify, reverse, or cure a serious or life-threatening disease. Clinical data derived from the ongoing ATALANTA-1 study with GLPG5101 in patients...

Continue reading

Ringkjøbing Landbobank’s quarterly report for the first half of 2025

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeOther stakeholders 6 August 2025Ringkjøbing Landbobank’s quarterly report for the first half of 2025 The bank’s board of directors and general management today approved the report for the first half of 2025. The bank delivers core earnings of DKK 1,580 million and net profit of DKK 1,191 million in the first half of the year. The net profit is equivalent to a 21% p.a. return on equity. Core earnings(DKK million) H1 2025 H1 2024 2024 2023 2022 2021Total core income 2,090 2,051 4,068 3,828 2,862 2,433Total expenses and depreciation 534 508 1,044 963 891 817Core earnings before impairment charges for loans 1,556 1,543 3,024 2,865 1,971 1,616Impairment charges for loans etc. +24 +1 +3 -1 -2 -68Core earnings 1,580 1,544 3,027 2,864 1,969 1,548Result for the portfolio...

Continue reading

Sampo Group’s results for January–June 2025

Sampo plc, half-year financial report, 6 August 2025 at 8:30 am EEST Sampo Group’s results for January–June 2025Like-for-like top-line growth of 8 per cent, supported by continued strong momentum in the private businesses in the Nordics and in the UK. Favourable claims environment throughout the first half and positive underlying trend in the Nordics supported underwriting margins, leading to an improved combined ratio of 83.6 per cent. The underwriting result increased by 25 per cent on a currency adjusted basis to EUR 729 million on the back of strong growth and margin improvement. Operating EPS strengthened by 13 per cent to EUR 0.25, driven by the strong underwriting performance offsetting lower investment returns and an increase in the share count. Following the strong second quarter performance, the outlook for 2025 underwriting...

Continue reading

Upward adjustment of expectations for 2025

Nasdaq CopenhagenEuronext DublinLondon Stock Exchange        Other stakeholders                 Date: 6 August 2025 Upward adjustment of expectations for 2025 Ringkjøbing Landbobank is upwardly adjusting its expectations for net profit for 2025. The expectations for net profit for the year are upwardly adjusted from the DKK 1,800 – 2,200 million range to the DKK 2,000 – 2,350 million range. The upward adjustment is based on a continued good credit quality and a loss and impairment level that has developed better than originally budgeted for 2025. In addition, the bank’s total income for the full year is now expected to be at the same level as the total income in 2024. The expectations for net profit for 2025 are subject to uncertainty and depend on developments in the financial markets and macroeconomic conditions. Yours sincerely Ringkjøbing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.